AQR Capital Management LLC Sells 25,943 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

AQR Capital Management LLC decreased its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 48.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,273 shares of the company's stock after selling 25,943 shares during the period. AQR Capital Management LLC's holdings in Syndax Pharmaceuticals were worth $560,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Syndax Pharmaceuticals by 13.6% in the 1st quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company's stock worth $117,262,000 after acquiring an additional 591,631 shares during the period. Sofinnova Investments Inc. lifted its stake in shares of Syndax Pharmaceuticals by 33.9% in the 2nd quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company's stock worth $44,215,000 after acquiring an additional 545,129 shares during the period. StemPoint Capital LP boosted its holdings in shares of Syndax Pharmaceuticals by 0.6% in the first quarter. StemPoint Capital LP now owns 1,100,988 shares of the company's stock valued at $26,204,000 after acquiring an additional 6,494 shares in the last quarter. Iron Triangle Partners LP acquired a new position in shares of Syndax Pharmaceuticals during the first quarter valued at approximately $23,159,000. Finally, Kingdon Capital Management L.L.C. increased its position in shares of Syndax Pharmaceuticals by 19.9% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 894,993 shares of the company's stock valued at $21,301,000 after purchasing an additional 148,700 shares during the period.

Analysts Set New Price Targets

Several research analysts have issued reports on SNDX shares. JPMorgan Chase & Co. dropped their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating on the stock in a report on Tuesday, August 6th. Citigroup raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a "buy" rating in a report on Friday, August 16th. Bank of America upped their price target on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research report on Thursday, August 15th. HC Wainwright boosted their target price on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. Finally, Barclays raised their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an "overweight" rating in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Syndax Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $35.78.

Syndax Pharmaceuticals Price Performance

SNDX traded down $0.07 during midday trading on Tuesday, hitting $19.75. 784,820 shares of the company's stock traded hands, compared to its average volume of 1,072,608. The company has a market cap of $1.68 billion, a PE ratio of -5.86 and a beta of 0.91. The stock's fifty day simple moving average is $19.34 and its 200-day simple moving average is $20.66. Syndax Pharmaceuticals, Inc. has a one year low of $11.22 and a one year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($0.91) by $0.11. The company had revenue of $3.50 million during the quarter. Syndax Pharmaceuticals's revenue was up 3499999990.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.64) earnings per share. On average, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).